- Home
- EIC vs AKBA Comparison
EIC vs AKBA Comparison
Compare EIC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- AKBA
- Stock Information
- Founded
- EIC N/A
- AKBA 2007
- Country
- EIC United States
- AKBA United States
- Employees
- EIC N/A
- AKBA N/A
- Industry
- EIC Finance/Investors Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- AKBA Health Care
- Exchange
- EIC Nasdaq
- AKBA Nasdaq
- Market Cap
- EIC 287.1M
- AKBA 336.2M
- IPO Year
- EIC 2019
- AKBA 2014
- Fundamental
- Price
- EIC $15.37
- AKBA $1.83
- Analyst Decision
- EIC
- AKBA Strong Buy
- Analyst Count
- EIC 0
- AKBA 1
- Target Price
- EIC N/A
- AKBA $7.50
- AVG Volume (30 Days)
- EIC 116.0K
- AKBA 2.4M
- Earning Date
- EIC 11-14-2023
- AKBA 11-07-2024
- Dividend Yield
- EIC 13.63%
- AKBA N/A
- EPS Growth
- EIC N/A
- AKBA N/A
- EPS
- EIC 0.80
- AKBA N/A
- Revenue
- EIC N/A
- AKBA $169,879,000.00
- Revenue This Year
- EIC N/A
- AKBA N/A
- Revenue Next Year
- EIC N/A
- AKBA $30.85
- P/E Ratio
- EIC $20.31
- AKBA N/A
- Revenue Growth
- EIC N/A
- AKBA N/A
- 52 Week Low
- EIC $13.00
- AKBA $0.80
- 52 Week High
- EIC $16.48
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- EIC 35.79
- AKBA 46.55
- Support Level
- EIC $15.11
- AKBA $1.74
- Resistance Level
- EIC $15.35
- AKBA $1.90
- Average True Range (ATR)
- EIC 0.16
- AKBA 0.09
- MACD
- EIC -0.04
- AKBA -0.03
- Stochastic Oscillator
- EIC 20.83
- AKBA 20.93
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.